TICKERNOMICS Sign up
Last Update: 2024-12-27 15:30:48
Amotiv Limited ( AOV.TO ) https://www.gud-knight.com
3.64USD
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Country:
Canada
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-7.71%
AOV.TO
SPY
32.66%
-10.67%
AOV.TO
SPY
108.59%
-37.35%
AOV.TO
SPY
302.52%
-38.51%
AOV.TO
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
368.76
264.24
0.04
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-28.88
1.49
0.66
9.17
0.00
5.73
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
3.07
48.15
17.60
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
5.4608
1.87
1.23
0.31
Other Earnings and Cash Flow Stats:
Amotiv Limited ( AOV.TO ) Net Income TTM ($MM) is -12.77
Amotiv Limited ( AOV.TO ) Operating Income TTM ($MM) is 4.27
Amotiv Limited ( AOV.TO ) Owners' Earnings Annual ($MM) is 0.00
Amotiv Limited ( AOV.TO ) Current Price to Owners' Earnings ratio is 0.00
Amotiv Limited ( AOV.TO ) EBITDA TTM ($MM) is 41.52
Amotiv Limited ( AOV.TO ) EBITDA Margin is 17.60%
Capital Allocation:
Amotiv Limited ( AOV.TO ) has paid 0.00 dividends per share and bought back 3.857949 million shares in the past 12 months
Amotiv Limited ( AOV.TO ) has reduced its debt by 4.1932246715257 million USD in the last 12 months
Capital Structure:
Amotiv Limited ( AOV.TO ) Interest-bearing Debt ($MM) as of last quarter is 37
Amotiv Limited ( AOV.TO ) Annual Working Capital Investments ($MM) are -2
Amotiv Limited ( AOV.TO ) Book Value ($MM) as of last quarter is 562
Amotiv Limited ( AOV.TO ) Debt/Capital as of last quarter is 6%
Other Balance Sheet Stats:
Amotiv Limited ( AOV.TO ) has 46 million in cash on hand as of last quarter
Amotiv Limited ( AOV.TO ) has 86 million of liabilities due within 12 months, and long term debt 45 as of last quarter
Amotiv Limited ( AOV.TO ) has 101 common shares outstanding as of last quarter
Amotiv Limited ( AOV.TO ) has 0 million USD of preferred stock value
Academic Scores:
Amotiv Limited ( AOV.TO ) Altman Z-Score is 2.40 as of last quarter
Amotiv Limited ( AOV.TO ) Piotroski Score is 7.00 as of last quarter
Corporate Governance:
Amotiv Limited ( AOV.TO ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Amotiv Limited ( AOV.TO ) for the amount of $ on
33.60% of Amotiv Limited ( AOV.TO ) is held by insiders, and 9.62% is held by institutions
Amotiv Limited ( AOV.TO ) went public on 1970-01-01
Other Amotiv Limited ( AOV.TO ) financial metrics:
FCF:37.04
Unlevered Free Cash Flow:10.92
EPS:-0.14
Operating Margin:3.07
Gross Profit Margin:48.15
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-2.44
Beta:0.31
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Amotiv Limited ( AOV.TO ) :
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.